Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Nipah virus outbreaks: still small but extremely lethal.

Spiropoulou CF.

J Infect Dis. 2018 Oct 26. doi: 10.1093/infdis/jiy611. [Epub ahead of print] No abstract available.

PMID:
30365002
2.

CD4 T cells, CD8 T cells, and monocytes coordinate to prevent Rift Valley fever virus encephalitis.

Harmon JR, Spengler JR, Coleman-McCray JD, Nichol ST, Spiropoulou CF, McElroy AK.

J Virol. 2018 Sep 26. pii: JVI.01270-18. doi: 10.1128/JVI.01270-18. [Epub ahead of print]

PMID:
30258000
3.

The S Genome Segment Is Sufficient to Maintain Pathogenicity in Intra-Clade Lassa Virus Reassortants in a Guinea Pig Model.

Welch SR, Scholte FEM, Albariño CG, Kainulainen MH, Coleman-McCray JD, Guerrero LW, Chakrabarti AK, Klena JD, Nichol ST, Spengler JR, Spiropoulou CF.

Front Cell Infect Microbiol. 2018 Jul 11;8:240. doi: 10.3389/fcimb.2018.00240. eCollection 2018.

4.

Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice.

Spengler JR, McElroy AK, Harmon JR, Coleman-McCray JD, Welch SR, Keck JG, Nichol ST, Spiropoulou CF.

PLoS One. 2018 Jul 20;13(7):e0201104. doi: 10.1371/journal.pone.0201104. eCollection 2018.

5.

Human Biomarkers of Outcome Following Rift Valley Fever Virus Infection.

McElroy AK, Harmon JR, Flietstra T, Nichol ST, Spiropoulou CF.

J Infect Dis. 2018 Oct 20;218(11):1847-1851. doi: 10.1093/infdis/jiy393.

PMID:
29955891
6.

Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.

Kainulainen MH, Spengler JR, Welch SR, Coleman-McCray JD, Harmon JR, Klena JD, Nichol ST, Albariño CG, Spiropoulou CF.

J Infect Dis. 2018 May 25;217(12):1957-1966. doi: 10.1093/infdis/jiy123.

PMID:
29800368
7.

Rift valley fever viral load correlates with the human inflammatory response and coagulation pathway abnormalities in humans with hemorrhagic manifestations.

de St Maurice A, Harmon J, Nyakarahuka L, Balinandi S, Tumusiime A, Kyondo J, Mulei S, Namutebi A, Knust B, Shoemaker T, Nichol ST, McElroy AK, Spiropoulou CF.

PLoS Negl Trop Dis. 2018 May 4;12(5):e0006460. doi: 10.1371/journal.pntd.0006460. eCollection 2018 May.

8.

Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.

Shrivastava-Ranjan P, Flint M, Bergeron É, McElroy AK, Chatterjee P, Albariño CG, Nichol ST, Spiropoulou CF.

MBio. 2018 May 1;9(3). pii: e00660-18. doi: 10.1128/mBio.00660-18.

9.

Susceptibility of paramyxoviruses and filoviruses to inhibition by 2'-monofluoro- and 2'-difluoro-4'-azidocytidine analogs.

Lo MK, Jordan PC, Stevens S, Tam Y, Deval J, Nichol ST, Spiropoulou CF.

Antiviral Res. 2018 May;153:101-113. doi: 10.1016/j.antiviral.2018.03.009. Epub 2018 Mar 27.

10.

Complete Genome Sequences of a Hantavirus Isolate from New York.

McMullan LK, Albariño CG, Ksiazek TG, Nichol ST, Spiropoulou CF.

Genome Announc. 2018 Mar 22;6(12). pii: e00188-18. doi: 10.1128/genomeA.00188-18.

11.

Development of a reverse genetics system for Sosuga virus allows rapid screening of antiviral compounds.

Welch SR, Chakrabarti AK, Wiggleton Guerrero L, Jenks HM, Lo MK, Nichol ST, Spiropoulou CF, Albariño CG.

PLoS Negl Trop Dis. 2018 Mar 9;12(3):e0006326. doi: 10.1371/journal.pntd.0006326. eCollection 2018 Mar.

12.

Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase.

Jordan PC, Liu C, Raynaud P, Lo MK, Spiropoulou CF, Symons JA, Beigelman L, Deval J.

PLoS Pathog. 2018 Feb 9;14(2):e1006889. doi: 10.1371/journal.ppat.1006889. eCollection 2018 Feb.

13.

Severity of Disease in Humanized Mice Infected With Ebola Virus or Reston Virus Is Associated With Magnitude of Early Viral Replication in Liver.

Spengler JR, Saturday G, Lavender KJ, Martellaro C, Keck JG, Nichol ST, Spiropoulou CF, Feldmann H, Prescott J.

J Infect Dis. 2017 Dec 27;217(1):58-63. doi: 10.1093/infdis/jix562.

PMID:
29087482
14.

Genome Sequences of Crimean-Congo Hemorrhagic Fever Virus Strains Isolated in South Africa, Namibia, and Turkey.

Zivcec M, Albarino CG, Guerrero LIW, Ksiazek TG, Nichol ST, Swanepoel R, Rollin PE, Spiropoulou CF.

Genome Announc. 2017 Oct 19;5(42). pii: e01060-17. doi: 10.1128/genomeA.01060-17.

15.

Rapid Determination of Ebolavirus Infectivity in Clinical Samples Using a Novel Reporter Cell Line.

Kainulainen MH, Nichol ST, Albariño CG, Spiropoulou CF.

J Infect Dis. 2017 Dec 12;216(11):1380-1385. doi: 10.1093/infdis/jix486.

PMID:
29029133
16.

Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus.

Welch SR, Scholte FEM, Flint M, Chatterjee P, Nichol ST, Bergeron É, Spiropoulou CF.

Antiviral Res. 2017 Nov;147:91-99. doi: 10.1016/j.antiviral.2017.10.008. Epub 2017 Oct 9.

PMID:
29024765
17.

Whole Blood-Based Multiplex Immunoassays for the Evaluation of Human Biomarker Responses to Emerging Viruses in Resource-Limited Regions.

Harmon JR, Nichol ST, Spiropoulou CF, McElroy AK.

Viral Immunol. 2017 Nov;30(9):671-674. doi: 10.1089/vim.2017.0088. Epub 2017 Sep 22.

18.

Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.

Scholte FEM, Zivcec M, Dzimianski JV, Deaton MK, Spengler JR, Welch SR, Nichol ST, Pegan SD, Spiropoulou CF, Bergeron É.

Cell Rep. 2017 Sep 5;20(10):2396-2407. doi: 10.1016/j.celrep.2017.08.040.

19.

A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

McElroy AK, Akondy RS, Harmon JR, Ellebedy AH, Cannon D, Klena JD, Sidney J, Sette A, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Nichol ST, Spiropoulou CF.

J Infect Dis. 2017 Jun 15;215(12):1862-1872. doi: 10.1093/infdis/jix201.

20.

Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.

Zivcec M, Guerrero LIW, Albariño CG, Bergeron É, Nichol ST, Spiropoulou CF.

Antiviral Res. 2017 Oct;146:112-120. doi: 10.1016/j.antiviral.2017.08.014. Epub 2017 Aug 24.

PMID:
28842265
21.

Human immune system mouse models of Ebola virus infection.

Spengler JR, Prescott J, Feldmann H, Spiropoulou CF.

Curr Opin Virol. 2017 Aug;25:90-96. doi: 10.1016/j.coviro.2017.07.028. Epub 2017 Aug 12. Review.

22.

4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency.

Hotard AL, He B, Nichol ST, Spiropoulou CF, Lo MK.

Antiviral Res. 2017 Aug;144:147-152. doi: 10.1016/j.antiviral.2017.06.011. Epub 2017 Jun 17.

23.

Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection.

Spengler JR, Kelly Keating M, McElroy AK, Zivcec M, Coleman-McCray JD, Harmon JR, Bollweg BC, Goldsmith CS, Bergeron É, Keck JG, Zaki SR, Nichol ST, Spiropoulou CF.

J Infect Dis. 2017 Dec 12;216(11):1386-1397. doi: 10.1093/infdis/jix215.

PMID:
28482001
24.

Flex-nucleoside analogues - Novel therapeutics against filoviruses.

Yates MK, Raje MR, Chatterjee P, Spiropoulou CF, Bavari S, Flint M, Soloveva V, Seley-Radtke KL.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2800-2802. doi: 10.1016/j.bmcl.2017.04.069. Epub 2017 Apr 22.

25.

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.

Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC, Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF.

Sci Rep. 2017 Mar 6;7:43395. doi: 10.1038/srep43395.

26.

Antibodies Against Henipa-Like Viruses in Brazilian Bats.

de Araujo J, Lo MK, Tamin A, Ometto TL, Thomazelli LM, Nardi MS, Hurtado RF, Nava A, Spiropoulou CF, Rota PA, Durigon EL.

Vector Borne Zoonotic Dis. 2017 Apr;17(4):271-274. doi: 10.1089/vbz.2016.2051. Epub 2017 Jan 19.

PMID:
28103156
27.

25-Hydroxycholesterol Inhibition of Lassa Virus Infection through Aberrant GP1 Glycosylation.

Shrivastava-Ranjan P, Bergeron É, Chakrabarti AK, Albariño CG, Flint M, Nichol ST, Spiropoulou CF.

MBio. 2016 Dec 20;7(6). pii: e01808-16. doi: 10.1128/mBio.01808-16.

28.

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG Jr, Bennett RS, Holbrook MR, Hensley LE, Jahrling PB.

PLoS One. 2016 Nov 30;11(11):e0166318. doi: 10.1371/journal.pone.0166318. eCollection 2016.

29.

A chronological review of experimental infection studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus.

Spengler JR, Estrada-Peña A, Garrison AR, Schmaljohn C, Spiropoulou CF, Bergeron É, Bente DA.

Antiviral Res. 2016 Nov;135:31-47. doi: 10.1016/j.antiviral.2016.09.013. Epub 2016 Oct 3. Review.

30.

Endocytic Pathways Used by Andes Virus to Enter Primary Human Lung Endothelial Cells.

Chiang CF, Flint M, Lin JS, Spiropoulou CF.

PLoS One. 2016 Oct 25;11(10):e0164768. doi: 10.1371/journal.pone.0164768. eCollection 2016.

31.

Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.

Welch SR, Guerrero LW, Chakrabarti AK, McMullan LK, Flint M, Bluemling GR, Painter GR, Nichol ST, Spiropoulou CF, Albariño CG.

Antiviral Res. 2016 Dec;136:9-18. doi: 10.1016/j.antiviral.2016.10.007. Epub 2016 Oct 19.

PMID:
27771389
32.

Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment.

Spengler JR, Lavender KJ, Martellaro C, Carmody A, Kurth A, Keck JG, Saturday G, Scott DP, Nichol ST, Hasenkrug KJ, Spiropoulou CF, Feldmann H, Prescott J.

J Infect Dis. 2016 Oct 15;214(suppl 3):S308-S318. Epub 2016 Sep 6.

33.

Ebola Virus Disease Diagnostics, Sierra Leone: Analysis of Real-time Reverse Transcription-Polymerase Chain Reaction Values for Clinical Blood and Oral Swab Specimens.

Erickson BR, Sealy TK, Flietstra T, Morgan L, Kargbo B, Matt-Lebby VE, Gibbons A, Chakrabarti AK, Graziano J, Presser L, Flint M, Bird BH, Brown S, Klena JD, Blau DM, Brault AC, Belser JA, Salzer JS, Schuh AJ, Lo M, Zivcec M, Priestley RA, Pyle M, Goodman C, Bearden S, Amman BR, Basile A, Bergeron É, Bowen MD, Dodd KA, Freeman MM, McMullan LK, Paddock CD, Russell BJ, Sanchez AJ, Towner JS, Wang D, Zemtsova GE, Stoddard RA, Turnsek M, Guerrero LW, Emery SL, Stovall J, Kainulainen MH, Perniciaro JL, Mijatovic-Rustempasic S, Shakirova G, Winter J, Sexton C, Liu F, Slater K, Anderson R, Andersen L, Chiang CF, Tzeng WP, Crowe SJ, Maenner MJ, Spiropoulou CF, Nichol ST, Ströher U.

J Infect Dis. 2016 Oct 15;214(suppl 3):S258-S262. Epub 2016 Aug 31.

34.

Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination.

Ellebedy AH, Jackson KJ, Kissick HT, Nakaya HI, Davis CW, Roskin KM, McElroy AK, Oshansky CM, Elbein R, Thomas S, Lyon GM, Spiropoulou CF, Mehta AK, Thomas PG, Boyd SD, Ahmed R.

Nat Immunol. 2016 Oct;17(10):1226-34. doi: 10.1038/ni.3533. Epub 2016 Aug 15.

35.

Laboratory Response to Ebola - West Africa and United States.

Sealy TK, Erickson BR, Taboy CH, Ströher U, Towner JS, Andrews SE, Rose LE, Weirich E, Lowe L, Klena JD, Spiropoulou CF, Rayfield MA, Bird BH.

MMWR Suppl. 2016 Jul 8;65(3):44-9. doi: 10.15585/mmwr.su6503a7.

PMID:
27389781
36.

Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

McElroy AK, Harmon JR, Flietstra TD, Campbell S, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Kratochvil CJ, Iwen PC, Smith PW, Ahmed R, Nichol ST, Spiropoulou CF.

Clin Infect Dis. 2016 Aug 15;63(4):460-7. doi: 10.1093/cid/ciw334. Epub 2016 Jun 27.

37.

Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome.

Bird BH, Shrivastava-Ranjan P, Dodd KA, Erickson BR, Spiropoulou CF.

Antiviral Res. 2016 Aug;132:66-9. doi: 10.1016/j.antiviral.2016.05.014. Epub 2016 May 24.

PMID:
27233645
38.

Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus.

Zivcec M, Scholte FE, Spiropoulou CF, Spengler JR, Bergeron É.

Viruses. 2016 Apr 21;8(4):106. doi: 10.3390/v8040106. Review.

39.

Ebola Virus Persistence in Semen of Male Survivors.

Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM 3rd, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, Nau GJ, Spiropoulou C, Nichol ST, Ströher U.

Clin Infect Dis. 2016 Jun 15;62(12):1552-1555. doi: 10.1093/cid/ciw202. Epub 2016 Apr 3.

PMID:
27045122
40.

In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses.

Lo MK, Shi PY, Chen YL, Flint M, Spiropoulou CF.

Antiviral Res. 2016 Jun;130:46-9. doi: 10.1016/j.antiviral.2016.03.013. Epub 2016 Mar 23.

41.

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S.

Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2. Erratum in: ACS Chem Biol. 2016 May 20;11(5):1463.

42.

Assessment of Inhibitors of Pathogenic Crimean-Congo Hemorrhagic Fever Virus Strains Using Virus-Like Particles.

Zivcec M, Metcalfe MG, Albariño CG, Guerrero LW, Pegan SD, Spiropoulou CF, Bergeron É.

PLoS Negl Trop Dis. 2015 Dec 1;9(12):e0004259. doi: 10.1371/journal.pntd.0004259. eCollection 2015 Dec.

43.

Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease.

Bird BH, Spengler JR, Chakrabarti AK, Khristova ML, Sealy TK, Coleman-McCray JD, Martin BE, Dodd KA, Goldsmith CS, Sanders J, Zaki SR, Nichol ST, Spiropoulou CF.

J Infect Dis. 2016 Mar 1;213(5):703-11. doi: 10.1093/infdis/jiv538. Epub 2015 Nov 17.

44.

The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.

McMullan LK, Flint M, Dyall J, Albariño C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF.

Antiviral Res. 2016 Jan;125:71-8. doi: 10.1016/j.antiviral.2015.10.010. Epub 2015 Oct 23.

PMID:
26526586
45.

A Molecular Sensor To Characterize Arenavirus Envelope Glycoprotein Cleavage by Subtilisin Kexin Isozyme 1/Site 1 Protease.

Oppliger J, da Palma JR, Burri DJ, Bergeron E, Khatib AM, Spiropoulou CF, Pasquato A, Kunz S.

J Virol. 2015 Oct 28;90(2):705-14. doi: 10.1128/JVI.01751-15. Print 2016 Jan 15.

46.

Utility of Oral Swab Sampling for Ebola Virus Detection in Guinea Pig Model.

Spengler JR, Chakrabarti AK, Coleman-McCray JD, Martin BE, Nichol ST, Spiropoulou CF, Bird BH.

Emerg Infect Dis. 2015 Oct;21(10):1816-9. doi: 10.3201/eid2110.150840.

47.

Ebola Virus Diagnostics: The US Centers for Disease Control and Prevention Laboratory in Sierra Leone, August 2014 to March 2015.

Flint M, Goodman CH, Bearden S, Blau DM, Amman BR, Basile AJ, Belser JA, Bergeron É, Bowen MD, Brault AC, Campbell S, Chakrabarti AK, Dodd KA, Erickson BR, Freeman MM, Gibbons A, Guerrero LW, Klena JD, Lash RR, Lo MK, McMullan LK, Momoh G, Massally JL, Goba A, Paddock CD, Priestley RA, Pyle M, Rayfield M, Russell BJ, Salzer JS, Sanchez AJ, Schuh AJ, Sealy TK, Steinau M, Stoddard RA, Taboy C, Turnsek M, Wang D, Zemtsova GE, Zivcec M, Spiropoulou CF, Ströher U, Towner JS, Nichol ST, Bird BH.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S350-8. doi: 10.1093/infdis/jiv361. Epub 2015 Jul 30.

PMID:
26232439
48.

RIG-I Mediates an Antiviral Response to Crimean-Congo Hemorrhagic Fever Virus.

Spengler JR, Patel JR, Chakrabarti AK, Zivcec M, García-Sastre A, Spiropoulou CF, Bergeron É.

J Virol. 2015 Oct;89(20):10219-29. doi: 10.1128/JVI.01643-15. Epub 2015 Jul 29.

49.

Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses.

Mohr EL, McMullan LK, Lo MK, Spengler JR, Bergeron É, Albariño CG, Shrivastava-Ranjan P, Chiang CF, Nichol ST, Spiropoulou CF, Flint M.

Antiviral Res. 2015 Aug;120:40-7. doi: 10.1016/j.antiviral.2015.05.003. Epub 2015 May 16.

50.

Relationship Between Ebola Virus Real-Time Quantitative Polymerase Chain Reaction-Based Threshold Cycle Value and Virus Isolation From Human Plasma.

Spengler JR, McElroy AK, Harmon JR, Ströher U, Nichol ST, Spiropoulou CF.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S346-9. doi: 10.1093/infdis/jiv187. Epub 2015 May 3.

Supplemental Content

Loading ...
Support Center